Particularly, CAR-T therapy uses genetic engineering to equip T cells with specific antigen receptors that can recognize specific antigens on the tumor surface, allowing T cells to bypass these evasion mechanisms and precisely identify tumor cells, avoiding the MHC-dependent recognition process (10, 12). The gene discussed is HLA-C; the disease is neoplasm.